We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Btg Plc | LSE:BTG | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 840.00 | 839.00 | 840.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
06/10/2016 08:36 | All cash in the bank.I wonder if the next bolt on might be sterling based.Any candidates? | fhmktg | |
06/10/2016 08:31 | CT - if Varithena sales hit £2m, if my memory serves me correctly, that would be a near doubling of sales!! So I think it will be less than that, BUT I still don't quite get your point as BTG have maintained all along the 2016-2017 will be an inflexion point, from static sales to growing sales, the bigger growth numbers as I understand it are not anticipated until 2017-2018 and beyond. BTG clearly still believe in Varithena, check out Louise's comments in the recent magazine article, I though they were encouraging. And, they are investing in a Canadian launch - why bother wth that if the product is floundering? All in all, I think this is the best news we could have anticipated. I'm happy. | spyder | |
06/10/2016 07:59 | If unsure then? | bill hunt | |
06/10/2016 07:55 | Will not surprise me if varithena revenue for first half is less than £2m. And what about expiry of Btg patent in dec 2016 on abiraterone? The combination patent out until 2026 is owned by j&j. | cockneytrader | |
06/10/2016 07:47 | Also Varithena also ready for uptake in Canada , so though it is slow it is starting to gain coverage. Overall a steady set of results , giving the company the strength to do an earning enhancing deal in the near term . | bargainbob | |
06/10/2016 07:15 | As expected. Varithena sales show gradual increase. Gradual means weak in business talk, hardly the strong growth as expected in 2016/17. | cockneytrader | |
04/10/2016 15:11 | Traders heaven today! | fhmktg | |
04/10/2016 12:28 | hope it shows potential to retain the £7 level this week | bargainbob | |
04/10/2016 10:16 | Close period update Thursday, fingers crossed! | fhmktg | |
26/9/2016 16:09 | No. It completed Phase III trials in Europe with good data, but was never put forward for approval. | cockneytrader | |
26/9/2016 15:48 | Is Varithena available in UK? On NHS or Private? | jadeticl3 | |
23/9/2016 15:50 | Great write up. | bargainbob | |
23/9/2016 13:16 | Message getting out? | fhmktg | |
23/9/2016 11:19 | What a cracking read CT, thanks for posting it.That should cause some re-thinking in potential investors.Has this been placed ahead of the announcement that the inflexion point has been reached with Varithena, or to plug any market traction to a further period of low income?The comments on patient and clinician feedback are particularly welcome. | fhmktg | |
23/9/2016 10:54 | an excellent overview review of btg now on their website. still think varithena will be a problem in the short term. | cockneytrader | |
21/9/2016 17:26 | Oh post 4102 | bargainbob | |
21/9/2016 17:25 | Invesco modestly increasing.Optimism or a whisper? | fhmktg | |
19/9/2016 14:37 | Bargainbob. 'However the city investors ...' That much we know for certain! | tratante | |
17/9/2016 16:10 | Needs to show good news on varithena before any take over. However the city investors will know months and maybe years before us. | bargainbob |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions